Literature DB >> 17894530

Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity.

Takanori Kubo1, Zhivko Zhelev, Hideki Ohba, Rumiana Bakalova.   

Abstract

The present study describes improved properties of 27-nt dsRNAs over 21-nt siRNAs, and accents on the possibility to use their modifications and conjugates for direct long-term gene silencing in viable cells and animals, avoiding conventional transfectants. Using a Renilla Luciferase gene-silencing system and cultured cell lines, we established that 27-nt dsRNAs possessed about three to five times higher "long-term" RNAi activity than 21-nt siRNAs and 21-nt dsRNAs. Moreover, if RNA duplexes were preincubated with cell-cultured medium for several hours before their transfection in cells, 21-mer completely lost its RNAi effect, while 27-mer, its amino modifications, thiol modifications, and cholesterol conjugates manifested a strong gene silencing. In attempts to clarify the reason(s) for the higher RNAi activity of 27-nt dsRNAs, we found that they were approximately 100 times more stable than 21-nt siRNA and 21-nt dsRNA in cell-cultured medium supplemented with 10% inactivated serum, approximately 50 times more stable in 90% inactivated serum, and approximately six times more stable in active serum. The 5' sense modification was selected as the most stable, accessible to Dicer, and with highest RNAi potential. The RNAi activity of 5' sense modifications was higher even than the activity of nonmodified 27-nt dsRNA. The 5' sense amino modification also did not influence the activity of 21-nt siRNA, right overhang 25/27-nt (R25D/27), and 25D/27-nt RNAs. The stability of 5' sense modified R25D/27-nt and 25D/27-nt RNAs in serum was lower than that of blunt 27-nt dsRNA. However, these asymmetric RNAs were more active than modified and nonmodified blunt 27-nt dsRNAs, which demonstrates the superiority of the asymmetric design. The 5' sense modifications were considered as most appropriate for conjugation with small signal molecules to facilitate the intracellular delivery of RNA duplex, to preserve its RNAi capacity, and to ensure a possibility for rapid long-term gene silencing in viable cells and animals. The 5' sense conjugation with cholesterol approved this assumption.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894530     DOI: 10.1089/oli.2007.0096

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  12 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

Review 2.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

3.  Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

Authors:  Michael A Collingwood; Scott D Rose; Lingyan Huang; Chris Hillier; Mohammad Amarzguioui; Merete T Wiiger; Harris S Soifer; John J Rossi; Mark A Behlke
Journal:  Oligonucleotides       Date:  2008-06

Review 4.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

5.  Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC.

Authors:  William Salomon; Karen Bulock; Jennifer Lapierre; Pamela Pavco; Tod Woolf; Joanne Kamens
Journal:  Nucleic Acids Res       Date:  2010-02-18       Impact factor: 16.971

6.  The XPO6 Exportin Mediates Herpes Simplex Virus 1 gM Nuclear Release Late in Infection.

Authors:  Hugo Boruchowicz; Josiane Hawkins; Kendra Cruz-Palomar; Roger Lippé
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

7.  Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants.

Authors:  Nicholas M Snead; Xiwei Wu; Arthur Li; Qi Cui; Kumi Sakurai; John C Burnett; John J Rossi
Journal:  Nucleic Acids Res       Date:  2013-04-24       Impact factor: 16.971

8.  Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development.

Authors:  Valérie Bégin-Lavallée; Élora Midavaine; Marc-André Dansereau; Pascal Tétreault; Jean-Michel Longpré; Ashley M Jacobi; Scott D Rose; Mark A Behlke; Nicolas Beaudet; Philippe Sarret
Journal:  Mol Pain       Date:  2016-06-15       Impact factor: 3.395

9.  Gene Therapy for Neuropathic Pain through siRNA-IRF5 Gene Delivery with Homing Peptides to Microglia.

Authors:  Tomoya Terashima; Nobuhiro Ogawa; Yuki Nakae; Toshiyuki Sato; Miwako Katagi; Junko Okano; Hiroshi Maegawa; Hideto Kojima
Journal:  Mol Ther Nucleic Acids       Date:  2018-02-27       Impact factor: 8.886

10.  The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy.

Authors:  Annabelle Biscans; Jillian Caiazzi; Sarah Davis; Nicholas McHugh; Jacquelyn Sousa; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2020-08-20       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.